Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers
2026年8月12日 更新者:Arjun Deb, MD
A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1
This is a Phase 1 single-blind, placebo-controlled, dose-escalation study designed to evaluate the safety of AD-NP1, a humanized monoclonal antibody targeting human ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1).
The study aims to assess the maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AD-NP1 in healthy volunteers.
Participants will be randomized to receive either AD-NP1 or placebo, with safety and efficacy monitored in accordance with Good Clinical Practice (GCP) guidelines.
The study also seeks to explore changes in health-related quality of life (HRQOL) during the trial.
研究概览
地位
地位
主动,不招人
干预/治疗
干预/治疗
研究类型
研究类型
介入性
注册 (估计的)
注册
36
阶段
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- UCLA Clinical and Translational Research Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
是的
描述
Inclusion Criteria:
- Body weight ≤ 90kg
- Ability to understand and the willingness to sign a written informed consent document
- Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
- Be in general good health without history of any of the conditions listed in exclusion criteria
- No use of any tobacco products for at least 6 months
- Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
- Sexually active male subjects must use a barrier method of contraception during the study
Screening laboratory values must meet the following criteria:
- WBC (>3,000 - <11,000/mm^3)
- Platelets (>100,000/mm^3)
- Hemoglobin (>10.5 gm/dl)
- Creatinine (<1.1 x upper limit of normal [ULN])
- BUN (<1.25 x ULN)
- AST (<1.1 x ULN)
- ALT (<1.1 x ULN)
- Alkaline Phosphatase (<1.1 x ULN)
- Bilirubin (<1.1 x ULN)
- Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
- Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
- Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
- Weight > 90 kg
- History of any of the following illnesses or conditions:
- a. Respiratory condition (such as asthma requiring daily medication)
- b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
- c. Blood dyscrasias
- d. Psychiatric disorder that precludes compliance with the clinical protocol
- e. Hepatitis
- Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
- History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
- History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
- Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
- Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
- Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
- Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
- Currently breast-feeding
- Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:单身的
手臂数量
8
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
安慰剂比较:Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
实验性的:Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
安慰剂比较:Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
实验性的:Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
安慰剂比较:Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
实验性的:Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
安慰剂比较:Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
大体时间:Day of infusion (Day 0) to 28 days post-dose
|
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
|
Day of infusion (Day 0) to 28 days post-dose
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Tolerated Dose of AD-NP1
大体时间:Day of infusion (Day 0) to 28 days post-dose
|
To be determined based on dose limiting toxicities (DLTs) and adverse events
|
Day of infusion (Day 0) to 28 days post-dose
|
|
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
大体时间:Baseline (pre-dose) up to Day 60 post-dose
|
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
大体时间:Baseline (pre-dose) up to Day 60 post-dose
|
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
大体时间:Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
|
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
|
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
大体时间:Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
大体时间:Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Plasma Uridine Concentration
大体时间:Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Cytidine Concentration
大体时间:Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Orotidine Concentration
大体时间:Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Adenine Concentration
大体时间:Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Carbamoyl Aspartate Concentration
大体时间:Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Immunogenicity of a single IV dose of AD-NP1
大体时间:Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
Determined by measuring levels of circulating anti-drug antibody in blood samples
|
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
|
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
大体时间:Baseline (pre-dose) up to Day 60 post-dose
|
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
学习开始
2026年6月2日
初级完成 (估计的)
初级完成
2028年1月1日
研究完成 (估计的)
研究完成
2028年5月1日
研究注册日期
首次提交
首次提交
2026年8月6日
首先提交符合 QC 标准的
首先提交符合 QC 标准的
2026年8月6日
首次发布 (实际的)
首次发布
2026年8月13日
研究记录更新
最后更新发布 (实际的)
最后更新发布
2026年8月14日
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
2026年8月12日
最后验证
最后验证
2026年8月1日
更多信息
与本研究相关的术语
关键字
其他研究编号
其他研究编号
- 25-1584
- PR250528 (其他赠款/资助编号:DOD-DEPARTMENT OF DEFENSE)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.